NeuroRx

NeuroRx: Leading Relief Therapeutics Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US. In Phase 3 with readout expected mid-January 2021. Also developing first Glx targeted antidepressant to address suicidality in bipolar depression. NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase III
Disease Space
Central Nervous System, COVID-19, Infectious Disease
Industry
Biotechnology
Listing
Private
Market Cap
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
913 North Market Street
Suite 200
Wilmington, DE 19801
United States

Company Participants at Solebury Trout Virtual Global Healthcare Conference Series

  • Jonathan Javitt, PhD, Vice Chairman